UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2021
Commission File Number: 001-35165
BRAINSWAY LTD.
(Translation of registrant's name into English)
19 Hartum Street
Bynet Building, 3rd Floor
Har HaHotzvim
Jerusalem, 9777518, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
EXHIBIT INDEX
Exhibit
Title
99.1
BrainsWay Reports First Quarter 2021 Financial Results and Operational Highlights
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BRAINSWAY LTD. | ||
| (Registrant) | ||
| Date: May 20, 2021 | /s/ Christopher R. von Jako, Ph.D | |
| Christopher R. von Jako, Ph.D | ||
| President and Chief Executive Officer | ||
EXHIBIT 99.1
BrainsWay Reports First Quarter 2021 Financial Results and Operational Highlights
Strong Revenue Growth of 47% Year-over-Year in Q1 2021
Successfully Executed Initial U.S. Controlled Market Release of Deep TMS for Smoking Addiction
Strengthened Balance Sheet Through Successful Equity Offering; Ended Q1 2021 with $58.5 Million in Cash
Conference Call to be held Today at 8:30 AM ET
CRESSKILL, N.J. and JERUSALEM, May 20, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported first quarter 2021 financial results and provided an operational update.
Recent Financial and Operational Highlights
“We are extremely pleased with the overall trends in our business, and are working to continue the strong momentum achieved late in 2020 and during the first quarter throughout the year,” stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. “Our revenues of $6.1 million represented a significant 47% increase over our first quarter of 2020, demonstrating the resiliency of our business and continued emergence from the COVID-19 pandemic. We marked a true milestone for our revolutionary approach to mental health treatment with the recent treatment of our 100,000th patient, and this was complemented by impressive commercial and regulatory achievements, including our successful follow-on raise of $45.2 million in gross proceeds, the controlled market release of our smoking addiction system, and the FDA’s clearance of our three-minute Theta Burst depression protocol. We believe these accomplishments position us well to generate long-term shareholder value and to advance in our mission to improve health and transform lives.”
First Quarter 2021 Financial Results
Conference Call and Webcast
BrainsWay’s management will host a conference call today, May 20, 2021, at 8:30 a.m. Eastern Time to discuss these results and answer questions.
Thursday, May 20, at 8:30 AM Eastern Time:
| United States: | 877-407-3982 |
| Israel: | 1 809 406 247 |
| International: | 201-493-6780 |
| Conference ID: | 13719155 |
| Webcast: | http://public.viavid.com/index.php?id=144607 |
To listen to a live webcast, please visit the Investors section of the BrainsWay website at www.BrainsWay.com. Please access the Company’s website at least 10 minutes ahead of the conference call to register. The webcast replay will be available on the website for two weeks following the completion of the call.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward- looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 20-F. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov.
Contacts:
BrainsWay:
Scott Areglado
SVP and Chief Financial Officer
Scott.Areglado@BrainsWay.com
Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
| BRAINSWAY LTD. | ||||||||||
| CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | ||||||||||
| U.S. dollars in thousands (except share and per share data) | ||||||||||
| March 31, | December 31, | |||||||||
| 2021 | 2020 | |||||||||
| ASSETS | Unaudited | Audited | ||||||||
| Current Assets | ||||||||||
| Cash and cash equivalents | $ | 58,280 | $ | 16,961 | ||||||
| Short-term deposits | 221 | 221 | ||||||||
| Trade receivables, net | 6,674 | 5,582 | ||||||||
| Other accounts receivable | 1,516 | 1,534 | ||||||||
| Total current assets | 66,691 | 24,298 | ||||||||
| Long-term deposits | 165 | 163 | ||||||||
| Leased systems | 4,538 | 4,966 | ||||||||
| System components and other property and equipment | 4,696 | 4,584 | ||||||||
| Total assets | $ | 76,090 | $ | 34,011 | ||||||
| LIABILITIES AND EQUITY | ||||||||||
| Current Liabilities | ||||||||||
| Trade payables | $ | 1,072 | $ | 781 | ||||||
| Other accounts payable | 3,557 | 3,769 | ||||||||
| Deferred revenue | 1,812 | 1,543 | ||||||||
| Liability in respect of research and development grants | 417 | 707 | ||||||||
| Total current liabilities | 6,858 | 6,800 | ||||||||
| Deferred revenue and other liabilities | 1,939 | 2,015 | ||||||||
| Liability in respect of research and development grants | 5,963 | 5,524 | ||||||||
| Warrants | 7 | 38 | ||||||||
| Total Liabilities | 14,767 | 14,377 | ||||||||
| Equity: | ||||||||||
| Share capital | 346 | 233 | ||||||||
| Share premium | 137,282 | 95,135 | ||||||||
| Share-based payment | 5,906 | 3,748 | ||||||||
|
Adjustments arising from translating financial statements from
functional currency to presentation currency |
(2,188 | ) |
(2,188
|
) | ||||||
| Accumulated deficit | (80,023 | ) |
(77,294
|
) | ||||||
| Total Equity | 61,323 | 19,634 | ||||||||
| Total Liabilities and Equity | $ | 76,090 | $ | 34,011 | ||||||
| BRAINSWAY LTD. | ||||||||||
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||||||||||
| U.S. dollars in thousands (except share and per share data) | ||||||||||
| For the three months ended March 31, | ||||||||||
| 2021 | 2020 | |||||||||
| (Unaudited) | ||||||||||
| Revenues | $ | 6,121 | $ | 4,157 | ||||||
| Cost of revenues | 1,515 | 1,015 | ||||||||
| Gross profit | 4,606 | 3,142 | ||||||||
| Research and development expenses, net | 1,228 | 1,795 | ||||||||
| Selling and marketing expenses | 3,578 | 3,713 | ||||||||
| General and administrative expenses | 1,956 | 1,255 | ||||||||
| Total operating expenses | 6,762 | 6,763 | ||||||||
| Operating loss | (2,156 | ) | (3,621 | ) | ||||||
| Finance (expense) income, net | (412) | 309 | ||||||||
| Loss before income taxes | (2,568 | ) | (3,312 | ) | ||||||
| Income taxes | 160 | 130 | ||||||||
| Net loss and total comprehensive loss | $ | (2,728 | ) | $ | (3,442 | ) | ||||
| Basic and diluted net comprehensive loss per share | $ | (0.11 | ) | $ | (0.15 | ) | ||||